<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?OLF?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Genet</journal-id><journal-id journal-id-type="publisher-id">pgen</journal-id><journal-title>PLoS Genetics</journal-title><issn pub-type="ppub">1553-7390</issn><issn pub-type="epub">1553-7404</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1371/journal.pgen.0030135</article-id><article-id pub-id-type="publisher-id">07-PLGE-RA-0119R2</article-id><article-id pub-id-type="sici">plge-03-08-10</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Genetics and Genomics</subject><subject>Genetics and Genomics</subject><subject>Genetics and Genomics</subject><subject>Genetics and Genomics</subject></subj-group><subj-group subj-group-type="System Taxonomy"><subject>Mus (Mouse)</subject></subj-group></article-categories><title-group><article-title>Unbiased Gene Expression Analysis Implicates the huntingtin Polyglutamine Tract in Extra-mitochondrial Energy Metabolism</article-title><alt-title alt-title-type="running-head">HD CAG Does Not Directly Inhibit the Mitochondrion</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Jong-Min</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ivanova</surname><given-names>Elena V</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="n104">&#x000a4;</xref></contrib><contrib contrib-type="author"><name><surname>Seong</surname><given-names>Ihn Sik</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cashorali</surname><given-names>Tanya</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kohane</surname><given-names>Isaac</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gusella</surname><given-names>James F</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>MacDonald</surname><given-names>Marcy E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor1">&#x0002a;</xref></contrib></contrib-group><aff id="aff1"><label>1</label> Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts, United States of America </aff><aff id="aff2"><label>2</label> Children's Hospital Informatics Program, Children's Hospital, Boston, Massachusetts, United States of America </aff><aff id="aff3"><label>3</label> Huntington's Disease Society of America Coalition for the Cure Mitochondria and Energy Metabolism Team, New York, New York, United States of America </aff><contrib-group><contrib contrib-type="editor"><name><surname>Orr</surname><given-names>Harry</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">University of Minnesota, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; To whom correspondence should be addressed. E-mail: <email>macdonam&#x00040;helix.mgh.harvard.edu</email></corresp></author-notes><pub-date pub-type="ppub"><month>8</month><year>2007</year></pub-date><pub-date pub-type="epub"><day>17</day><month>8</month><year>2007</year></pub-date><pub-date pub-type="epreprint"><day>27</day><month>6</month><year>2007</year></pub-date><volume>3</volume><issue>8</issue><elocation-id>e135</elocation-id><history><date date-type="received"><day>20</day><month>2</month><year>2007</year></date><date date-type="accepted"><day>27</day><month>6</month><year>2007</year></date></history><copyright-statement><bold>Copyright:</bold> &#x000a9; 2007 Lee et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2007</copyright-year><!--<related-article related-article-type="preprint" xlink:title="Research Article" xlink:href="10.1371/journal.pgen.0030135.eor" id="RA1" ext-link-type="doi" xlink:type="simple" >Unbiased Gene Expression Analysis Implicates the huntingtin Polyglutamine Tract in Extra-mitochondrial Energy Metabolism</related-article>--><abstract><p>The Huntington's disease (HD) CAG repeat, encoding a polymorphic glutamine tract in huntingtin, is inversely correlated with cellular energy level, with alleles over &#x0223c;37 repeats leading to the loss of striatal neurons. This early HD neuronal specificity can be modeled by respiratory chain inhibitor 3-nitropropionic acid (3-NP) and, like 3-NP, mutant huntingtin has been proposed to directly influence the mitochondrion, via interaction or decreased PGC-1&#x003b1; expression. We have tested this hypothesis by comparing the gene expression changes due to mutant huntingtin accurately expressed in <italic>STHdh<sup>Q111/Q111</sup></italic> cells with the changes produced by 3-NP treatment of wild-type striatal cells. In general, the HD mutation did not mimic 3-NP, although both produced a state of energy collapse that was mildly alleviated by the PGC-1&#x003b1;-coregulated nuclear respiratory factor 1 (Nrf-1). Moreover, unlike 3-NP, the <italic>HD</italic> CAG repeat did not significantly alter mitochondrial pathways in <italic>STHdh<sup>Q111/Q111</sup></italic> cells, despite decreased <italic>Ppargc1a</italic> expression. Instead, the HD mutation enriched for processes linked to huntingtin normal function and Nf-&#x003ba;B signaling. Thus, rather than a direct impact on the mitochondrion, the polyglutamine tract may modulate some aspect of huntingtin's activity in extra-mitochondrial energy metabolism. Elucidation of this <italic>HD</italic> CAG-dependent pathway would spur efforts to achieve energy-based therapeutics in HD.</p></abstract><abstract abstract-type="summary"><title>Author Summary</title><sec id="st1"><title/><p>Huntington's disease (HD) is a tragic neurodegenerative disorder caused by a CAG repeat that specifies the size of a glutamine tract in the huntingtin protein, such that the longer the tract, the earlier the loss of striatal brain cells. A correlation of polyglutamine tract size has also implicated huntingtin in the proper functioning of mitochondria, the cell's energy factories. Here we have tested the prevailing hypothesis, that huntingtin may directly affect the mitochondrion, by using comprehensive gene expression analysis to judge whether the HD mutation may replicate the effects of 3-nitropropionic acid (3-NP), a compound known to inhibit mitochondria, with loss of striatal neurons. We found that, while mutant huntingtin and 3-NP both elicited energy starvation, the gene responses to the HD mutation, unlike the responses to 3-NP, did not highlight damage to mitochondria, but instead revealed effects on huntingtin-dependent processes. Thus, rather than direct inhibition, the polyglutamine tract size appears to modulate some normal activity of huntingtin that indirectly influences the management of the mitochondrion. Understanding the precise nature of this extra-mitochondrial process would critically guide efforts to achieve effective energy-based therapeutics in HD.</p></sec></abstract><counts><page-count count="10"/></counts><custom-meta-wrap><custom-meta><meta-name>citation</meta-name><meta-value>Lee JM, Ivanova EV, Seong IS, Cashorali T, Kohane I, et al. (2007) Unbiased gene expression analysis implicates the huntingtin polyglutamine tract in extra-mitochondrial energy metabolism. PLoS Genet 3(8): e135. doi:<ext-link ext-link-type="doi" xlink:href="10.1371/journal.pgen.0030135">10.1371/journal.pgen.0030135</ext-link></meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec id="s1"><title>Introduction</title><p>The CAG trinucleotide repeat in the Huntington's disease gene <italic>(HD)</italic> is highly polymorphic in humans, with alleles ranging from &#x0223c;6 to &#x0003e;100 units encoding a variable polyglutamine tract in huntingtin, a large (&#x0003e;350 kDa) HEAT domain protein &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b001">1</xref>&#x0005d;. The gene was discovered because alleles over &#x0223c;35&#x02013;37 units, whether inherited in one copy or, in rare cases, two copies, are associated with the onset of Huntington's disease (HD) symptoms, including dance-like movements, cognitive decline, and psychiatric disturbance &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b001">1</xref>&#x0005d;. This intriguing disease-initiating mechanism, while relatively insensitive to dosage, is exquisitely progressive with allele size, such that the age at onset of HD symptoms is progressively decreased as CAG length is increased &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b001">1</xref>&#x0005d;.</p><p>The early HD pathology comprises the selective loss of medium-size spiny neurons in the striatum that forms the HD pathological grading system &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b002">2</xref>&#x0005d;. The ability of mitochondrial respiratory chain poisons such as succinate dehydrogenase inhibitor 3-nitropropionic acid (3-NP) to produce HD-like striatal-specific cell loss has implied a role for mitochondrial dysfunction in HD pathogenesis &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b003">3</xref>&#x0005d;. Indeed, numerous studies have demonstrated that deficits in measures of energy metabolism become manifest in presymptomatic and symptomatic HD brain and peripheral tissues &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b004">4</xref>&#x02013;<xref ref-type="bibr" rid="pgen-0030135-b011">11</xref>&#x0005d;.</p><p>Investigations of the early consequences of the <italic>HD</italic> CAG repeat in human lymphoblastoid cell lines have recently implicated the polyglutamine tract size in huntingtin in modulating cellular ATP/ADP ratio across the entire non-HD and HD range &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b012">12</xref>&#x0005d;. The longest alleles were associated with the lowest ATP/ADP ratios, while alleles in the non-HD range were associated with progressively higher energy levels &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b012">12</xref>&#x0005d;. Moreover, consistent with a role for the polyglutamine tract in influencing an intrinsic huntingtin function in energy metabolism, the targeted deletion of the short seven-glutamine tract from murine huntingtin yielded elevated cellular ATP, with early senescence, and improved motor performance in <italic>Hdh</italic><sup>&#x00394;Q/&#x00394;Q</sup> mice &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b013">13</xref>&#x0005d;.</p><p>The shared downstream consequences of the <italic>HD</italic> CAG tract and 3-NP have implied that the polyglutamine tract in huntingtin, like 3-NP, may directly affect the mitochondrion &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b014">14</xref>&#x0005d;. Huntingtin is detected throughout the cell, in the nucleus and in the cytoplasm, where it can associate with mitochondria &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b015">15</xref>&#x0005d;, implicating a direct &#x0201c;toxic&#x0201d; interaction &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b015">15</xref>&#x02013;<xref ref-type="bibr" rid="pgen-0030135-b017">17</xref>&#x0005d;. However, recent findings, including studies in <italic>STHdh<sup>Q111/Q111</sup></italic> striatal cells, with a knock-in juvenile onset CAG repeat accurately expressed as endogenous huntingtin with 111 glutamines &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b018">18</xref>&#x0005d;, suggested that mutant huntingtin may influence mitochondrial biogenesis/function by decreasing <italic>Ppargc1a</italic> transcription &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b019">19</xref>,<xref ref-type="bibr" rid="pgen-0030135-b020">20</xref>&#x0005d;. This gene encodes peroxisome proliferative activated receptor gamma, coactivator 1 alpha (PGC-1&#x003b1;), a key cofactor for Nrf-1 and other mitochondrial transcription regulators.</p><p>To probe the earliest consequences of the <italic>HD</italic> CAG mechanism, we tested the mitochondrial hypothesis by using unbiased gene expression analysis to monitor the extent to which the accurate expression of the <italic>HD</italic> CAG repeat, in <italic>STHdh<sup>Q111/Q111</sup></italic> striatal cells, may reproduce the consequences of 3-NP challenge. The results confirmed a shared downstream energy collapse but did not indict direct 3-NP-like effects of the <italic>HD</italic> CAG repeat on the mitochondrion. Instead, the data have elevated the candidacy of extra-mitochondrial pathways in huntingtin modulation of energy metabolism.</p></sec><sec id="s2"><title>Result/Discussion</title><p>We and others have demonstrated previously that <italic>STHdh<sup>Q111/Q111</sup></italic> cells, compared to wild-type <italic>STHdh<sup>Q7/Q7</sup></italic> cells (expressing endogenous seven-glutamine huntingtin), exhibited mitochondrial energy phenotypes similar to the effects of 3-NP treatment, including decreased mitochondrial respiration &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b021">21</xref>&#x0005d; and ATP synthesis &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b012">12</xref>,<xref ref-type="bibr" rid="pgen-0030135-b021">21</xref>,<xref ref-type="bibr" rid="pgen-0030135-b022">22</xref>&#x0005d;. However, <italic>STHdh<sup>Q111/Q111</sup></italic> cells also have been shown to display phenotypes opposite to the effects reported for 3-NP challenge, such as increased, instead of decreased, levels of the reactive oxygen species (ROS) scavenger glutathione &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b023">23</xref>&#x0005d;, suggesting that 3-NP might not precisely mimic the effects of the HD mutation.</p><p>To explore this notion, we examined additional energy phenotypes and observed, as reported for 3-NP challenge, that the HD mutation decreased mitochondrial membrane potential (<xref ref-type="fig" rid="pgen-0030135-g001">Figure 1</xref>A) and elevated the lactate/pyruvate ratio (<xref ref-type="fig" rid="pgen-0030135-g001">Figure 1</xref>B) indicative of altered energy homeostasis. Indeed, in human lymphoblastoid cells, this ratio was increased in severity with <italic>HD</italic> CAG repeat size (<xref ref-type="fig" rid="pgen-0030135-g001">Figure 1</xref>C), demonstrating that mitochondrial dysfunction is likely to be a consequence of the <italic>HD</italic> CAG size-dependent mechanism. However, while 3-NP, as reported &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b024">24</xref>&#x0005d;, was associated with increased ROS, as measured by hydrogen peroxide levels, the <italic>STHdh<sup>Q111/Q111</sup></italic> cells, compared to wild-type cells, exhibited decreased ROS (<xref ref-type="fig" rid="pgen-0030135-g001">Figure 1</xref>D). Moreover, while 3-NP treated wild-type cells, as expected, displayed decreased succinate dehydrogenase activity, the longer <italic>HD</italic> CAG repeat expressed in the <italic>STHdh<sup>Q111/Q111</sup></italic> cells did not significantly change the activity of this respiratory chain component (<xref ref-type="fig" rid="pgen-0030135-g001">Figure 1</xref>E). Thus, while superficially similar, the energy phenotypes displayed by mutant striatal cells did not in detail recapitulate the effects of 3-NP challenge, implying distinct underlying pathways.</p><fig id="pgen-0030135-g001" position="float"><label>Figure 1</label><caption><title>Mitochondrial Phenotypes Altered by the HD Mutation or 3-NP Treatment</title><p>(A) Mitochondrial membrane potential, denoted by the FL1/FL2 ratio, was significantly decreased by the HD mutation in ST<italic>Hdh<sup>Q111/Q111</sup></italic> cells (ST111/111), compared to wild-type ST<italic>Hdh<sup>Q7/Q7</sup></italic> cells (ST7/7).</p><p>(B) Lactate/pyruvate ratio was significantly increased in both ST<italic>Hdh<sup>Q111/Q111</sup></italic> cells (ST111/111) and 3-NP treated wild-type ST<italic>Hdh<sup>Q7/Q7</sup></italic> cells (ST7/7 &#x0002b; 3-NP), compared to untreated ST<italic>Hdh<sup>Q7/Q7</sup></italic> cells (ST7/7).</p><p>(C) Lactate/pyruvate ratio was significantly increased in HD lymphoblastoid cells as the length of the longer of the two <italic>HD</italic> CAG alleles was increased, from the typical normal size (18 CAG) to the adult onset HD (42&#x02013;50 CAG) and juvenile onset HD (66&#x02013;70) ranges.</p><p>(D) ROS, monitored by hydrogen peroxide concentration, was significantly decreased in ST<italic>Hdh<sup>Q111/Q111</sup></italic> cells (ST111/111) compared to ST<italic>Hdh<sup>Q7/Q7</sup></italic> cells (ST7/7) but was dramatically increased in wild-type cells following treatment with 3-NP.</p><p>(E) Succinate dehydrogenase activity was similar in ST<italic>Hdh<sup>Q111/Q111</sup></italic> cells (ST111/111) and ST<italic>Hdh<sup>Q7/Q7</sup></italic> cells (ST7/7), but was significantly decreased by 3-NP treatment of wild-type ST<italic>Hdh</italic><sup>Q7/Q7</sup> cells (ST7/7 &#x0002b; 3-NP).</p><p>In all panels, asterisk denotes significant difference (<italic>p</italic> &#x0003c; 0.05) from ST7/7 by Student <italic>t</italic>-test.</p></caption><graphic xlink:href="pgen.0030135.g001"/></fig><p>To delineate the effects of the <italic>HD</italic> CAG repeat and 3-NP treatment, without making a priori assumptions about the underlying biology, we performed global analysis to monitor the expression of the mitochondrial and the nuclear genomes. As sequences for genes located on the mitochondrial genome were not represented on the murine Affymetrix MG 430 2.0 arrays microarrays, which we used to analyze the nuclear genome (below), the expression of nine of the 13 mitochondrial genes encoding respiratory components was assessed using specific RT-PCR assays. The mRNA levels for each of these genes was dramatically reduced in 3-NP treated cells, compared to untreated wild-type striatal cells, whereas mRNA levels did not differ significantly between <italic>STHdh<sup>Q111/Q111</sup></italic> and wild-type cells (<xref ref-type="supplementary-material" rid="pgen-0030135-sg001">Figure S1</xref>). Thus, consistent with unchanged succinate dehydrogenase activity, mutant huntingtin did not reproduce the effects of 3-NP on the mitochondrial genome, implying that the energy deficits in <italic>STHdh<sup>Q111/Q111</sup></italic> cells might instead stem from altered expression of the nuclear genes that regulate the mitochondrion.</p><p>We then performed unbiased analysis of the nuclear genome expression datasets to determine the extent to which the consequences of the <italic>HD</italic> CAG repeat may mirror the effects of 3-NP challenge. The results of principle component (<xref ref-type="fig" rid="pgen-0030135-g002">Figure 2</xref>A) and cluster analysis (<xref ref-type="fig" rid="pgen-0030135-g002">Figure 2</xref>B) of all probes demonstrated that, whereas the replicate datasets were highly related, the wild-type, 3-NP treated, and mutant cell datasets were quite distinct. Thus, rather than giving rise to similar effects, which may differ in magnitude, the consequences of the <italic>HD</italic> CAG repeat and 3-NP appeared to be fundamentally different. Indeed, at a stringent false discovery rate (FDR) (<italic>q</italic> &#x0003c; 0.005), approximately the same proportion of all probes (3&#x00025;) was significantly altered either by the <italic>HD</italic> CAG repeat mutation (comparing mutant versus wild-type cells) (<xref ref-type="supplementary-material" rid="pgen-0030135-st001">Table S1</xref>) or by 3-NP challenge (comparing 3-NP treated wild-type versus wild-type cells) (<xref ref-type="supplementary-material" rid="pgen-0030135-st002">Table S2</xref>), with the <italic>HD</italic> CAG yielding some changes of larger magnitude (fold-change) than 3-NP. However, little overlap was detected between the two probe lists (summarized in <xref ref-type="fig" rid="pgen-0030135-g002">Figure 2</xref>C and <xref ref-type="fig" rid="pgen-0030135-g002">2</xref>E), yielding low correlation coefficients between <italic>HD</italic> CAG and 3-NP changed probes (<xref ref-type="fig" rid="pgen-0030135-g002">Figure 2</xref>D). Indeed, for the most part, these represented different genes, which are plotted by chromosome in <xref ref-type="supplementary-material" rid="pgen-0030135-sg002">Figure S2</xref>. Thus, while the impact, in terms of number and magnitude of changes, was similar, HD mutation did not reproduce the molecular effects of 3-NP.</p><fig id="pgen-0030135-g002" position="float"><label>Figure 2</label><caption><title><italic>HD</italic> CAG Mutation and 3-NP Treatment Produced Distinct Signatures</title><p>(A) Plot of unsupervised principal component analysis of triplicate datasets for wild-type striatal cells (ST7/7/), mutant striatal cells (ST111/111), and wild-type cells treated with 3-NP (ST7/7&#x0002b;3-NP), revealing discrete gene expression space for the <italic>HD</italic> CAG repeat (comparison of ST111/111 and ST7/7) and 3-NP treatment (comparison of ST7/7&#x0002b;3-NP and ST7/7).</p><p>(B) Dendrogram plot, generated by average linkage clustering algorithm analysis of the expression values of all probes, indicated proper clustering of triplicate samples within each group and revealed that the mutant cell group (ST111/111) was more closely related to the wild-type cell group (ST7/7) than to the 3-NP treated wild-type cell samples (ST7/7&#x0002b;3-NP). Arrows depict the data set comparisons to generate changes due to the HD CAG and 3-NP treatment.</p><p>(C) Diagram summarizing the identification of significantly altered probe signals using a stringent FDR <italic>q</italic>-value 0.005, which revealed 630 probes different between mutant and wild-type striatal cells (HD CAG) and 889 probes changed between wild-type cells and wild-type cells treated with 3-NP (3-NP), with 83 probes significant in both comparisons (shared). Of these, 70 &#x00025; were concordantly changed.</p><p>(D) Plot of the correlation coefficients between the <italic>HD</italic> CAG- and 3-NP-changes for all probes (white), for the <italic>HD</italic> CAG significant probes (red), and for the 3-NP significant probes (green), demonstrating the distinct nature of the changes in the two comparisons.</p><p>(E) Volcano plots of fold-change versus FDR <italic>q-</italic>value for probes significant (<italic>q</italic> &#x0003c; 0.005) in the <italic>HD</italic> CAG comparison (red) and those same probes in the 3-NP comparison (green) (left panel) or the converse (right panel), showing the small overlap and more dynamic expression changes for the <italic>HD</italic> CAG repeat, compared to 3-NP treatment.</p></caption><graphic xlink:href="pgen.0030135.g002"/></fig><p>The mitochondrial hypothesis predicted that both the HD mutation and 3-NP treatment would alter mitochondrial energy genes, prompting an examination of the small fraction (0.18&#x00025;) of all probes significantly altered by both insults. These represented 83 known genes (plotted by chromosome in <xref ref-type="supplementary-material" rid="pgen-0030135-sg003">Figure S3</xref> and listed in <xref ref-type="supplementary-material" rid="pgen-0030135-st003">Table S3</xref>), which did not highlight the mitochondrion but instead spotlighted decreased cytosolic energy production (<xref ref-type="fig" rid="pgen-0030135-g003">Figure 3</xref>). More sensitive tests of groups of genes in functional pathways, using the Gene Ontology (GO) biological process (<xref ref-type="fig" rid="pgen-0030135-g004">Figure 4</xref>A) and sigPathway gene set analysis &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b025">25</xref>&#x0005d; (<xref ref-type="fig" rid="pgen-0030135-g004">Figure 4</xref>B), confirmed that the HD mutation and 3-NP were both associated with highly significant decreases in carbohydrate metabolism and, as reported previously &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b026">26</xref>&#x0005d;, lipid (sterol/cholesterol) biosynthesis (<xref ref-type="fig" rid="pgen-0030135-g004">Figure 4</xref>C). Thus, striatal cells, unlike glia or other cell types, may possess a limited capacity to adjust glycolytic flux in response to changes in mitochondrial ATP synthesis &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b027">27</xref>&#x0005d;, thereby providing a potential explanation for the ability of 3-NP to mimic the early loss of striatal neurons in HD striatum.</p><fig id="pgen-0030135-g003" position="float"><label>Figure 3</label><caption><title><italic>HD</italic> CAG and 3-NP Shared Decreased Expression of Glycolytic Genes</title><p>The energy metabolism pathway gene expression changes common to mutant striatal cells (<italic>HD</italic> CAG, red) and 3-NP treated wild-type striatal cells (3-NP, green) are shown, with fold-change, compared to wild-type striatal cells, highlighting decreased cytosolic glycolytic processes (numbered 1&#x02013;11). The HD mutation but not 3-NP treatment was associated with increased expression of <italic>Ldh2</italic> and of enzymes in the formation and breakdown of glutathione or the toxic product methylglyoxyal. Single asterisk denotes FDR <italic>q</italic>-value &#x0003c;0.05 double asterisks denote FDR <italic>q-</italic>value &#x0003c; 0.005.</p></caption><graphic xlink:href="pgen.0030135.g003"/></fig><fig id="pgen-0030135-g004" position="float"><label>Figure 4</label><caption><title>Pathways Common to <italic>HD</italic> CAG and 3-NP Reveal Decreased Carbohydrate and Lipid Metabolism, with <italic>HD</italic> CAG-Specific Pathways Reminiscent of huntingtin Normal Function</title><p>(A) Venn diagrams summarize the results of GO analysis (biological process), showing the numbers of significantly altered (Increase, Decrease) <italic>HD</italic> CAG-specific, 3-NP-specific and shared GO terms, with the major categories of pathways listed below.</p><p>(B) Venn diagram, statistical criteria, and NT<sub>k</sub> value-based heatmap summarize the results of sigPathway analysis to distinguish gene sets that were <italic>HD</italic> CAG specific (Group 1), 3-NP specific (Group 5), or highly significant in both the <italic>HD</italic> CAG and 3-NP comparisons (Group 3). Groups 2 and 4 were judged marginally significant. High absolute NT<sub>k</sub> value indicates high significance and &#x0002b;NT<sub>k</sub> and &#x02013;NT<sub>k</sub> denote enrichment in the control group (ST7/7) and the experimental group (ST111/111 or ST7/7&#x0002b;3-NP), respectively. The major categories of enriched gene sets, with the direction of change denoted by arrows, are listed.</p><p>(C) A list of the 15 pathways that were found to be common to the HD mutation and 3-NP treatment, as judged significant in both GO and sigPathway analysis. All were enriched in wild-type cells (ST7/7) compared to mutant striatal cells or 3-NP treated wild-type cells and denoted glycolysis and lipid/sterol metabolism.</p></caption><graphic xlink:href="pgen.0030135.g004"/></fig><p>Although the notion that the HD mutation and 3-NP might commonly alter the expression of nuclear encoded mitochondrial genes did not appear to be borne out, inspection of the data did reveal significant changes in a few mitochondria-related energy genes in mutant striatal cells, which, notably, were unchanged by 3-NP (<xref ref-type="fig" rid="pgen-0030135-g003">Figure 3</xref>). <italic>Ppargc1a</italic> (encoding PGC-1&#x003b1;) was decreased, as reported previously &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b019">19</xref>&#x0005d;. Mitochondrial components in the transfer electrons from NADH to the respiratory chain <italic>(Ndufa12</italic> and <italic>Ndufa3)</italic> or in the transport of hydrogen ions <italic>(Atp6v0e2)</italic> were decreased. By contrast, mRNAs encoding the iron sulfur-binding factor of complex III <italic>(Uqcr)</italic> and a nonenzymatic component of the ATP synthase complex <italic>(Atp5j2)</italic> were elevated. Moreover, consistent with elevated glutathione &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b023">23</xref>&#x0005d;, the expression of genes that detoxify free radical derivatives <italic>(Ldh2, Gss,</italic> and <italic>Glo1)</italic> was increased, suggesting that altered redox state may contribute distinctly to low energy (and lipid) metabolism in mutant striatal cells.</p><p>The decrease in <italic>Ppargc1a</italic> mRNA implied that mitochondrial regulatory transcription factors such as Nrf-1, which are coregulated by PGC-1&#x003b1;, might be expected to improve energy metabolism in mutant cells. Indeed, over-expression of Nrf-1 in <italic>STHdh<sup>Q111/Q111</sup></italic> cells altered the mRNA levels of known Nrf-1 target genes (<xref ref-type="supplementary-material" rid="pgen-0030135-st004">Table S4</xref>) but, as reported for PGC-1&#x003b1; &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b019">19</xref>&#x0005d;, only mildly improved both cellular lactate/pyruvate ratio (<xref ref-type="fig" rid="pgen-0030135-g005">Figure 5</xref>A) and cell survival following respiratory chain inhibition (<xref ref-type="fig" rid="pgen-0030135-g005">Figure 5</xref>B). Thus, coupled with the apparent dearth of changes in mitochondrial factors, the modest effects of boosting Nrf-1 strongly suggested that mutant huntingtin may not directly perturb the mitochondrion.</p><fig id="pgen-0030135-g005" position="float"><label>Figure 5</label><caption><title>Nrf-1 Ameliorated Mutant Striatal Cell Lactate/Pyruvate and Survival</title><p>(A) Bar plot of lactate/pyruvate ratio in ST<italic>Hdh<sup>Q111/Q111</sup></italic> striatal cells transiently transfected with pSG5 control plasmid (white) or Nrf-1 expression plasmid (black), demonstrating improvement with the latter. Asterisk denotes <italic>p</italic> &#x0003c; 0.05 by Student's <italic>t</italic>-test.</p><p>(B) Bar plot of viability of ST<italic>Hdh<sup>Q111/Q111</sup></italic> cells that were transiently transfected with control pSG5 plasmid (white) or Nrf-1 plasmid (black), challenged with various concentrations of 3-NP, showing increased survival with the latter. Asterisk denotes <italic>p</italic> &#x0003c; 0.05 by Student's <italic>t</italic>-test.</p></caption><graphic xlink:href="pgen.0030135.g005"/></fig><p>Consequently, to more rigorously examine this possibility, we used gene set enrichment analysis (GSEA) to specifically determine whether mitochondrial pathways or processes may be perturbed by 3-NP or the HD mutation. GSEA examines, as a group, genes that form a functional pathway, thereby capturing small effect sizes that when considered in single gene analyses may not have reached our stringent statistical threshold. We tested two sets of &#x0223c;1,500 nuclear genes that were either GO annotated or predicted by the integrative genomics program MAESTRO &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b028">28</xref>&#x0005d; to encode mitochondrial products, as well as a third set comprising the group of 902 genes that were common to both lists (<xref ref-type="supplementary-material" rid="pgen-0030135-st005">Table S5</xref>; <xref ref-type="fig" rid="pgen-0030135-g006">Figure 6</xref>A and <xref ref-type="fig" rid="pgen-0030135-g006">6</xref>B). The GSEA results, plotted as enrichment scores in <xref ref-type="fig" rid="pgen-0030135-g006">Figure 6</xref>C, demonstrated that, compared to wild-type cells, each of the gene sets was highly enriched by 3-NP treatment. In striking contrast, no significant enrichment of any of the mitochondrial gene sets was detected in <italic>STHdh<sup>Q111/Q111</sup></italic> cells. Thus, these findings, which were consistent with the results of the mitochondrial genome analysis (<xref ref-type="supplementary-material" rid="pgen-0030135-sg001">Figure S1</xref>), clearly revealed that the HD mutation did not reproduce the direct effects of 3-NP on the mitochondrion. Therefore, contrary to predictions from decreased <italic>Ppargc1a</italic> mRNA or interactions of mutant huntingtin with the mitochondrion &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b014">14</xref>&#x02013;<xref ref-type="bibr" rid="pgen-0030135-b017">17</xref>,<xref ref-type="bibr" rid="pgen-0030135-b019">19</xref>,<xref ref-type="bibr" rid="pgen-0030135-b020">20</xref>&#x0005d;, our results consistently implied that the <italic>HD</italic> CAG mechanism may primarily influence energy metabolism via extra-mitochondrial cellular pathways.</p><fig id="pgen-0030135-g006" position="float"><label>Figure 6</label><caption><title>3-NP but Not the HD mutation altered Nuclear-Encoded Mitochondrial Gene Expression</title><p>(A) Venn diagram depicting the numbers of probes in two overlapping nuclear gene sets, either annotated by GO cellular component (GO) or predicted by MAESTRO &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b028">28</xref>&#x0005d; to encode mitochondrial gene products, with those identified in both procedures forming a third gene set (Overlap).</p><p>(B) Bar plot of probe number percentage versus FDR <italic>q</italic>-value for each of the mitochondrial probe sets (MAESTRO, GO, overlap) revealed that fewer mitochondrial components were altered in the <italic>HD</italic> CAG comparison (red) than in the 3-NP comparison (green), with only a small subset concordantly altered by both insults (yellow).</p><p>(C) Plots of GSEA ranked metric and ES revealed that in each case the mitochondrial gene sets were significantly enriched only in wild-type cells treated with 3-NP (ST7/7&#x0002b;3-NP) and not in mutant striatal cells (ST111/111), compared to wild-type striatal cells (ST7/7).</p></caption><graphic xlink:href="pgen.0030135.g006"/></fig><p>Since our data supported the view that the processes by which the HD mutation and 3-NP may lead to energy starvation were largely distinct, we reasoned that the pathways that did mediate the effects of the huntingtin polyglutamine tract would be those that were not affected by 3-NP challenge. To support this approach, we tested whether the early presymptomatic consequences of the <italic>HD</italic> CAG repeat in medium-size spiny striatal neurons in vivo might be recapitulated by accurate expression of the expanded <italic>HD</italic> CAG repeat in cultured <italic>STHdh<sup>Q111/Q111</sup></italic> cells or by 3-NP challenge of wild-type cells. Microarray analysis of mRNA from medium-size spiny striatal neurons, obtained by laser capture microscopy (LCM) from post-mortem brain, has been reported &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b029">29</xref>&#x0005d;. The major class of LCM genes judged to be the most significantly altered by the <italic>HD</italic> CAG in that study, all with decreased expression, yielded a set of 38 mouse genes (<xref ref-type="supplementary-material" rid="pgen-0030135-st014">Table S14</xref>) that were tested by GSEA in our striatal cell <italic>HD</italic> CAG and 3-NP datasets. The results demonstrated that this human LCM gene set was significantly decreased in the <italic>STHdh<sup>Q111/Q111</sup></italic> cells (enrichment score &#x0005b;ES&#x0005d; 0.51, <italic>p-</italic>value 0.000, FDR <italic>q-</italic>value 0.180) but was not altered in the 3-NP treated cells (ES 0.38, <italic>p-</italic>value 0.271, FDR <italic>q-</italic>value 0.713). Thus, the early molecular consequences of the <italic>HD</italic> CAG repeat in striatal neurons in human brain also become manifest as a consequence of accurate expression of the expanded repeat in the cultured <italic>STHdh<sup>Q111/Q111</sup></italic> cells but these were not reproduced by 3-NP challenge. This supported the approach of attempting to identify the processes by which huntingtin may modulate energy metabolism by examination of <italic>HD</italic> CAG repeat&#x02013;specific changes.</p><p>Therefore, stringent statistical filtering criteria were used to identify those gene sets that were enriched in mutant striatal cells but not in 3-NP treated wild-type cells (<xref ref-type="supplementary-material" rid="pgen-0030135-st006">Tables S6</xref>&#x02013;<xref ref-type="supplementary-material" rid="pgen-0030135-st012">S12</xref>). Remarkably, a major class of pathways uniquely enriched in <italic>STHdh<sup>Q111/Q111</sup></italic> cells, summarized in <xref ref-type="fig" rid="pgen-0030135-g004">Figure 4</xref>A and <xref ref-type="fig" rid="pgen-0030135-g004">4</xref>B, pointed to processes implicated in huntingtin's essential normal activities &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b030">30</xref>&#x02013;<xref ref-type="bibr" rid="pgen-0030135-b033">33</xref>&#x0005d;: development/morphogenesis (central nervous system, mesoderm, and embryo); growth, cell motility, migration, and locomotion; cell adhesion; neuronal processes; and TGF-&#x003b2; and BMP signaling. A minor class, which denoted increased gap junction channel (connexin), phosphate, and anion transport, may also prove to be related to huntingtin function. These results, therefore, strongly implicated huntingtin normal function in the capacity of the polyglutamine tract to influence mitochondrial function and cellular energy metabolism in <italic>STHdh<sup>Q111/Q111</sup></italic> cells.</p><p>Notably, this finding is consistent with a genetic gain-of-function hypothesis for the mechanism that initiates the HD pathogenic process. The polyglutamine tract size may progressively influence energy homeostasis by increasing some intrinsic huntingtin activity. Alternatively, it may capitalize on an opportunity afforded by huntingtin function to modulate an unrelated cellular component.</p><p>What might this normal huntingtin activity be? One possibility, inferred from previous work with huntingtin-deficient cells &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b034">34</xref>,<xref ref-type="bibr" rid="pgen-0030135-b035">35</xref>&#x0005d;, as well as with <italic>STHdh<sup>Q111/Q111</sup></italic> cells &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b018">18</xref>&#x0005d;, may reflect a role for huntingtin in intracellular iron trafficking. However, huntingtin's normal activities impact a broad range of cellular processes, from vesicle trafficking to the proper regulation of gene transcription &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b033">33</xref>,<xref ref-type="bibr" rid="pgen-0030135-b036">36</xref>,<xref ref-type="bibr" rid="pgen-0030135-b037">37</xref>&#x0005d;. As a starting point, therefore, we reasoned that worthy candidates for huntingtin modulation of energy metabolism might be found among the transcriptional regulators that most frequently orchestrate the gene changes in <italic>STHdh<sup>Q111/Q111</sup></italic> cells, but not 3-NP treated cells.</p><p>Unbiased transcription factor analysis coupled with GSEA yielded five <italic>HD</italic> CAG&#x02013;specific candidates (<xref ref-type="fig" rid="pgen-0030135-g007">Figure 7</xref>). Interestingly, NRSF/REST, associated with altered expression of genes in <italic>STHdh<sup>Q111/Q111</sup></italic> cells and in HD brain &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b037">37</xref>&#x0005d;, did not emerge as a candidate, and NRSF/REST target genes or genes with upstream RE1 binding sites were not enriched as a consequence of the <italic>HD</italic> CAG repeat (unpublished data). The top candidates for <italic>HD</italic> CAG specific regulators were CAAT-Box (e.g., NF-Y, cEBP, and CTF) and nuclear factor kappa B (Nf-&#x003ba;B), with weaker support for Nrf-1 and Sp-1. Most of these candidates, including Nrf-1, have been shown to exert extra-mitochondrial effects on energy metabolism, affecting, e.g., fatty oxidation, glycolysis, glutathione synthesis, and cell stress-sensing &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b038">38</xref>&#x02013;<xref ref-type="bibr" rid="pgen-0030135-b040">40</xref>&#x0005d;. Moreover, by associating exclusively with mutant huntingtin (or fragment), PGC-1&#x003b1;, a coregulator with Nrf-1, Sp-1, and its coregulator TAF4, as well as core components of Pol II transcriptional machinery (TFIID, TFIIF) have been implicated in HD pathogenesis &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b019">19</xref>,<xref ref-type="bibr" rid="pgen-0030135-b041">41</xref>&#x02013;<xref ref-type="bibr" rid="pgen-0030135-b043">43</xref>&#x0005d;.</p><fig id="pgen-0030135-g007" position="float"><label>Figure 7</label><caption><title>Transcription Factor Analysis to Identify <italic>HD</italic> CAG-Specific Regulators</title><p>(A) A plot of the normalized frequency of putative transcription factor binding sites identified from MAPPER database, for genes altered by the HD mutation (<italic>HD</italic> CAG).</p><p>(B) A plot of the normalized frequency of putative transcription factor binding sites identified from MAPPER database, for genes altered by 3-NP treatment (3-NP).</p><p>(C) Results of GSEA of candidate transcription factors that may frequently regulate target genes altered in mutant, compared to wild-type, striatal cells (<italic>HD</italic> CAG) or 3-NP treated, compared to untreated wild-type, striatal cells (3-NP), showing ES and FDR <italic>q-</italic>value statistic.</p></caption><graphic xlink:href="pgen.0030135.g007"/></fig><p>However, the mechanism by which the <italic>HD</italic> CAG modulates cellular energy levels was manifest even at non-HD-causing lengths, in the cadre of normal huntingtin function &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b012">12</xref>&#x0005d;. Nf-&#x003ba;B/Dorsal/RelB has been linked previously to huntingtin's normal function &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b044">44</xref>&#x0005d;. Nf-&#x003ba;B was a modifier of huntingtin carboxyl terminal fragment&#x02013;induced phenotypes in <italic>Drosophila</italic> &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b044">44</xref>&#x0005d;. Furthermore, endogenous normal human huntingtin can associate with the p50 subunit of Nf-&#x003ba;B &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b044">44</xref>&#x0005d;, which binds to target gene promoters in a redox-dependent manner &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b045">45</xref>&#x0005d;. This raises a new hypothesis that merits investigation in a variety of suitable polymorphic <italic>HD</italic> CAG systems, namely, that huntingtin polyglutamine tract length may influence Nf-&#x003ba;B-mediated signaling, perhaps via redox sensing, either as a cause or a consequence of modulating energy metabolism.</p><p>In summary, the results of this study demonstrated that the early (presymptomatic) consequences of the juvenile onset <italic>HD</italic> CAG allele, accurately expressed in <italic>STHdh<sup>Q111/Q111</sup></italic> striatal cells, did not in most details mimic mitochondrial respiratory chain inhibitor 3-NP, although both metabolic challenges produced a common response&#x02014;the collapse of mitochondrial and cytosolic energy processes. This reveals the limited utility of 3-NP lesion models for uncovering the pathways by which the polyglutamine tract in huntingtin may influence energy metabolism or for prioritizing agents that may modify these processes. Indeed, the data uniformly refute the widely held view of a direct mutant huntingtin-specific effect on the mitochondrion. Instead, our data implicate an effect of the polyglutamine tract on some normal activity of the huntingtin protein in extra-mitochondrial energy metabolism, perhaps redox sensing.</p><p>It is interesting to note that redox sensing cell signaling, via ROS-dependent pathways, is emerging as a regulator of glucose and lipid metabolism in health, aging, and disease &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b046">46</xref>&#x0005d;. If huntingtin proves to be involved, the molecules and gene products that modify oxidation-sensitive signaling in metabolic disorders may become candidates for modifying huntingtin-regulated mitochondrial metabolism in HD. By the same token, agents that modify redox sensing signaling in HD may also be of interest in cancer and a variety of complex metabolic disorders.</p></sec><sec sec-type="materials|methods" id="s3"><title>Materials and Methods</title><sec id="s3a"><title>Cell culture and 3-NP treatment.</title><p>ST<italic>Hdh<sup>Q7/Q7</sup></italic> and ST<italic>Hdh<sup>Q111/Q111</sup></italic> cells, generated from striatal primordia of wild-type <italic>Hdh<sup>Q7/Q7</sup></italic> and homozygous mutant <italic>Hdh<sup>Q111/Q111</sup></italic> knock-in mouse embryos, respectively &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b018">18</xref>&#x0005d;, were cultured in DMEM (33 &#x000b0;C, 5&#x00025; CO<sub>2</sub>, 10&#x00025; FBS, and 400 &#x003bc;g/ml G418). Challenge of ST<italic>Hdh<sup>Q7/Q7</sup></italic> cells with 3-NP (1 mM) was for 48 h. Previously genotyped human lymphoblastoid cell lines (<italic>HD</italic> CAG 17/18, 15/42, 21/43, 21/66, 19/70, 41/48, and 45/50) were cultured in RPMI-1640 (37 &#x000b0;C, 5&#x00025; CO<sub>2</sub>, and 5&#x00025; FBS).</p></sec><sec id="s3b"><title>Mitochondrial membrane potential, succinate dehydrogenase activity, ROS, and lactate/pyruvate ratio.</title><p>Mitochondrial membrane potential was measured by incubation of cells with JC-1 (2.5 &#x003bc;g/ml) for 20 min at 33 &#x000b0;C, followed by flow cytometry (FACScalibur, <ext-link ext-link-type="uri" xlink:href="http://www.bdbiosciences.com/">http://www.bdbiosciences.com/</ext-link>), counting 10<sup>4</sup> cells in the FL1 (monomer) and FL2 (aggregate) channels and calculating FL2/FL1 ratio.</p><p>Succinate dehydrogenase activity, measured using succinate as a substrate and 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium as an electron acceptor, was normalized by protein concentration &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b047">47</xref>&#x0005d;. ROS levels were monitored by determinations of hydrogen peroxide concentration, using a chemiluminescent hydrogen peroxide detection kit (Assay Designs, <ext-link ext-link-type="uri" xlink:href="http://www.assaydesigns.com/">http://www.assaydesigns.com/</ext-link>). Data were quantified compared to a standard curve, and normalized to cell number. Lactate and pyruvate concentrations in cleared lysates (3&#x00025; perchloric acid, sonication) were determined by HPLC analysis (Aminex column, Bio-Rad Laboratories, <ext-link ext-link-type="uri" xlink:href="http://www.bio-rad.com/">http://www.bio-rad.com/</ext-link>; 0.6 ml/min 0.05 mM H<sub>2</sub>SO<sub>4</sub>; UV detection at 210 nm) using appropriate standards. All measurements derive from triplicate experiments, using duplicate samples. Data are given as the mean, &#x0002b;/&#x02212; one standard deviation.</p></sec><sec id="s3c"><title>Mitochondrial genome gene expression analysis.</title><p>Reverse transcription PCR (RT-PCR) analysis for the genes listed in <xref ref-type="supplementary-material" rid="pgen-0030135-st005">Table S5</xref> was performed (Bio-Rad iCycler) with gene-specific primer sets listed in <xref ref-type="supplementary-material" rid="pgen-0030135-st013">Table S13</xref>. The &#x00394;&#x00394;C<sub>T</sub> method was used to calculate gene expression levels, compared to &#x003b2;-actin control &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b048">48</xref>&#x0005d;.</p></sec><sec id="s3d"><title>Microarray analysis of nuclear genome gene expression.</title><p>Total RNA (5 &#x003bc;g), isolated from triplicate cell cultures, was converted using SuperScript II reverse transcriptase (Invitrogen. <ext-link ext-link-type="uri" xlink:href="http://www.invitrogen.com">http://www.invitrogen.com</ext-link>) to labeled cRNA, and 25 &#x003bc;g of labeled probe was hybridized to Affymetrix MG 430 2.0 arrays (<ext-link ext-link-type="uri" xlink:href="http://www.affymetrix.com">http://www.affymetrix.com</ext-link>). Expression data was generated and normalized using RMA &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b049">49</xref>&#x0005d; and significant probes were identified by FDR (<italic>q</italic> &#x0003c; 0.005) &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b050">50</xref>&#x0005d;. A selection of genes judged to be significantly altered according to these criteria was tested by semi-quantitative RT-PCR analysis (primer sets in <xref ref-type="supplementary-material" rid="pgen-0030135-st013">Table S13</xref>), with &#x0223c;80&#x00025; (13 of 16 randomly chosen genes) concordant with the microarray results. For pathway analysis, significant (<italic>p</italic> &#x0003c; 0.05) GO terms in significantly altered probe sets were identified by GO analysis (DAVID 2006) &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b051">51</xref>&#x0005d; and, using all probes, significantly enriched (<italic>q</italic> &#x0003c; 0.01) pathways were identified by permutation-based GSEA (sigPathway) &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b025">25</xref>&#x0005d;. For the GSEA comparison of the mouse and human presymptomatic striatal cell changes, the LCM gene set comprised the 38 most robust LCM genes, all decreased by the <italic>HD</italic> CAG repeat, drawn from the table in Hodges et al. &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b029">29</xref>&#x0005d;, that could be unambiguously mapped to a corresponding mouse locus. Cluster &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b052">52</xref>&#x0005d;, dChip &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b053">53</xref>&#x0005d;, and Bioconductor &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b054">54</xref>&#x0005d; were used for clustering and data visualization.</p></sec><sec id="s3e"><title>Nrf-1 transfection and cytotoxicity assay.</title><p>ST<italic>Hdh<sup>Q111/Q111</sup></italic> cells were transiently transfected with control vector (pSG5) or Nrf-1 mammalian cell expression plasmid (0.2 &#x003bc;g of plasmid/well) using lipofectamine as described by the manufacturer (Invitrogen). At 48 h post-transfection, lactate/pyruvate ratios were determined, as described above, and viability following 3-NP challenge was measured by MTS cytotoxicity assay (Promega, <ext-link ext-link-type="uri" xlink:href="http://www.promega.com/">http://www.promega.com/</ext-link>). Nrf-1 activity was judged by measuring the expression of a selection of Nrf-1 target genes (<xref ref-type="supplementary-material" rid="pgen-0030135-st004">Table S4</xref>), using semi-quantitative RT-PCR analysis with gene-specific primer sets (<xref ref-type="supplementary-material" rid="pgen-0030135-st013">Table S13</xref>).</p></sec><sec id="s3f"><title>Transcription factor analysis.</title><p>For significant genes, putative transcription factor binding sites were identified from the MAPPER database &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b055">55</xref>&#x0005d;, by searching 500 bp upstream from the transcription initiation site and then selecting the top ten transcription factors, by score, for each gene. A total of 4,400 hits (358 transcription factors) and 6,684 hits (371 transcription factors) were recorded for <italic>HD</italic> CAG and 3-NP treatment, respectively, and the frequency for each was then calculated relative to the total number of hits. As a statistical test, the 100 top target genes for each transcription factor that exhibited 2&#x00025; or higher frequency in each comparison were identified and used in the transcription factor analysis, to build a custom set for gene set enrichment analysis &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b056">56</xref>&#x0005d;.</p></sec></sec><sec sec-type="supplementary-material" id="s4"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pgen-0030135-sg001"><label>Figure S1</label><caption><title>Mitochondrially Encoded Gene Expression Levels</title><p>Bar plot of mRNA levels, determined in RT-PCR assays, for nine mitochondrially encoded genes encoding respiratory chain polypeptides in wild-type striatal cells (ST7/7), mutant striatal cells (ST111/111), and wild-type striatal cells treated with 3-NP (ST7/7&#x0002b;3-NP), revealing decreased expression with 3-NP but not the HD mutation.</p><p>(33 KB PPT)</p></caption><media xlink:href="pgen.0030135.sg001.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pgen-0030135-sg002"><label>Figure S2</label><caption><title><italic>HD</italic> CAG and 3-NP Mostly Alter the Expression of Different Genes</title><p>The significant (FDR <italic>q</italic> &#x0003c; 0.005) gene changes associated with the HD mutation in mutant versus wild-type striatal cells (<italic>HD</italic> CAG) or with 3-NP treatment of wild-type cells versus untreated wild-type cells (3-NP) are depicted by chromosomal location and can be viewed in detail using probe ID (<xref ref-type="supplementary-material" rid="pgen-0030135-st001">Tables S1</xref> and <xref ref-type="supplementary-material" rid="pgen-0030135-st002">S2</xref>) and dChip software &#x0005b;<xref ref-type="bibr" rid="pgen-0030135-b053">53</xref>&#x0005d;.</p><p>(1.4 MB PPT)</p></caption><media xlink:href="pgen.0030135.sg002.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pgen-0030135-sg003"><label>Figure S3</label><caption><title>Genes Altered by Both the <italic>HD</italic> CAG and 3-NP Treatment</title><p>The shared significant (FDR <italic>q</italic> &#x0003c; 0.005) gene changes associated with the HD mutation in mutant versus wild-type striatal cells (<italic>HD</italic> CAG) or with 3-NP treatment of wild-type cells versus untreated wild-type cells (3-NP) are depicted by chromosomal location and can be viewed in detail using probe ID (<xref ref-type="supplementary-material" rid="pgen-0030135-st003">Table S3</xref>) and dChip software.</p><p>(477 KB PPT)</p></caption><media xlink:href="pgen.0030135.sg003.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pgen-0030135-st001"><label>Table S1</label><caption><title>Probes Significantly Altered by <italic>HD</italic> CAG</title><p>(122 KB XLS)</p></caption><media xlink:href="pgen.0030135.st001.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pgen-0030135-st002"><label>Table S2</label><caption><title>Probes Significantly Altered by 3-NP Treatment</title><p>(182 KB XLS)</p></caption><media xlink:href="pgen.0030135.st002.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pgen-0030135-st003"><label>Table S3</label><caption><title>Probes Significantly Altered by <italic>HD</italic> CAG and 3-NP Treatment</title><p>(30 KB XLS)</p></caption><media xlink:href="pgen.0030135.st003.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pgen-0030135-st004"><label>Table S4</label><caption><title>Nrf-1 Target Gene Expression</title><p>(30 KB DOC)</p></caption><media xlink:href="pgen.0030135.st004.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pgen-0030135-st005"><label>Table S5</label><caption><title>Nuclear Genes Encoding Mitochondrial Components</title><p>(275 KB XLS)</p></caption><media xlink:href="pgen.0030135.st005.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pgen-0030135-st006"><label>Table S6</label><caption><title>Shared Significant GO Terms by <italic>HD</italic> CAG and 3-NP Comparison</title><p>(47 KB DOC)</p></caption><media xlink:href="pgen.0030135.st006.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pgen-0030135-st007"><label>Table S7</label><caption><title><italic>HD</italic> CAG-Specific GO Terms</title><p>(45 KB DOC)</p></caption><media xlink:href="pgen.0030135.st007.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pgen-0030135-st008"><label>Table S8</label><caption><title>3-NP-Specific GO Terms</title><p>(147 KB DOC)</p></caption><media xlink:href="pgen.0030135.st008.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pgen-0030135-st009"><label>Table S9</label><caption><title>Shared Gene Sets by <italic>HD</italic> CAG and 3-NP (Group 3)</title><p>(33 KB DOC)</p></caption><media xlink:href="pgen.0030135.st009.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pgen-0030135-st010"><label>Table S10</label><caption><title><italic>HD</italic> CAG-Specific Gene Sets (Group 1)</title><p>(34 KB DOC)</p></caption><media xlink:href="pgen.0030135.st010.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pgen-0030135-st011"><label>Table S11</label><caption><title>3-NP-Specific Gene Sets (Group 5)</title><p>(165 KB DOC)</p></caption><media xlink:href="pgen.0030135.st011.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pgen-0030135-st012"><label>Table S12</label><caption><title>Significant Pathways Identified by Both GO Analysis and Gene Set Analysis</title><p>(60 KB DOC)</p></caption><media xlink:href="pgen.0030135.st012.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pgen-0030135-st013"><label>Table S13</label><caption><title>Primer Sets for Gene-Specific PCR Assays</title><p>(28 KB DOC)</p></caption><media xlink:href="pgen.0030135.st013.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pgen-0030135-st014"><label>Table S14</label><caption><title>LCM-Derived Gene Set</title><p>(22 KB XLS)</p></caption><media xlink:href="pgen.0030135.st014.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><sec id="s4a"><title>Accession Numbers</title><p>MIAME compliant microarray data were deposited at the Gene Expression Omnibus (GEO, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/">http://www.ncbi.nlm.nih.gov/geo/</ext-link>) with Accession number GSE3583.</p></sec></sec></body><back><ack><p>We thank Kathryn Coser and Toshi Shioda of the Massachusetts General Hospital Cancer Center Microarray Core for microarray hybridizations, Sarah Calvo for assistance with MAESTRO, and Richard Scarpulla for generously providing the Nrf-1 and control expression plasmids.</p></ack><glossary><title>Abbreviations</title><def-list><def-item><term>ES</term><def><p>enrichment score</p></def></def-item><def-item><term>FDR</term><def><p>false discovery rate</p></def></def-item><def-item><term>GSEA</term><def><p>gene set enrichment analysis</p></def></def-item><def-item><term>GO</term><def><p>gene ontology</p></def></def-item><def-item><term>HD</term><def><p>Huntington's disease</p></def></def-item><def-item><term><italic>HD,</italic></term><def><p>Huntington's disease gene</p></def></def-item><def-item><term>LCM</term><def><p>laser capture microscopy</p></def></def-item><def-item><term>3-NP</term><def><p>3-nitropropionic acid</p></def></def-item><def-item><term>ROS</term><def><p>reactive oxygen species</p></def></def-item><def-item><term>RT-PCR</term><def><p>reverse transcription PCR</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="pgen-0030135-b001"><citation citation-type="journal"><collab>The Huntington's Disease Collaborative Research Group</collab><year>1993</year><article-title>A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes</article-title><source>Cell</source><volume>72</volume><fpage>971</fpage><lpage>983</lpage><pub-id pub-id-type="pmid">8458085</pub-id></citation></ref><ref id="pgen-0030135-b002"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vonsattel</surname><given-names>JP</given-names></name><name><surname>Myers</surname><given-names>RH</given-names></name><name><surname>Stevens</surname><given-names>TJ</given-names></name><name><surname>Ferrante</surname><given-names>RJ</given-names></name><name><surname>Bird</surname><given-names>ED</given-names></name><etal/></person-group><year>1985</year><article-title>Neuropathological classification of Huntington's disease</article-title><source>J Neuropathol Exp Neurol</source><volume>44</volume><fpage>559</fpage><lpage>577</lpage><pub-id pub-id-type="pmid">2932539</pub-id></citation></ref><ref id="pgen-0030135-b003"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Borlongan</surname><given-names>CV</given-names></name><name><surname>Koutouzis</surname><given-names>TK</given-names></name><name><surname>Sanberg</surname><given-names>PR</given-names></name></person-group><year>1997</year><article-title>3-Nitropropionic acid animal model and Huntington's disease</article-title><source>Neurosci Biobehav Rev</source><volume>21</volume><fpage>289</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">9168265</pub-id></citation></ref><ref id="pgen-0030135-b004"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuhl</surname><given-names>DE</given-names></name><name><surname>Phelps</surname><given-names>ME</given-names></name><name><surname>Markham</surname><given-names>CH</given-names></name><name><surname>Metter</surname><given-names>EJ</given-names></name><name><surname>Riege</surname><given-names>WH</given-names></name><etal/></person-group><year>1982</year><article-title>Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan</article-title><source>Ann Neurol</source><volume>12</volume><fpage>425</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">6217782</pub-id></citation></ref><ref id="pgen-0030135-b005"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mazziotta</surname><given-names>JC</given-names></name><name><surname>Phelps</surname><given-names>ME</given-names></name><name><surname>Pahl</surname><given-names>JJ</given-names></name><name><surname>Huang</surname><given-names>SC</given-names></name><name><surname>Baxter</surname><given-names>LR</given-names></name><etal/></person-group><year>1987</year><article-title>Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease</article-title><source>N Engl J Med</source><volume>316</volume><fpage>357</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">2949152</pub-id></citation></ref><ref id="pgen-0030135-b006"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grafton</surname><given-names>ST</given-names></name><name><surname>Mazziotta</surname><given-names>JC</given-names></name><name><surname>Pahl</surname><given-names>JJ</given-names></name><name><surname>St George-Hyslop</surname><given-names>P</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><etal/></person-group><year>1990</year><article-title>A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease</article-title><source>Ann Neurol</source><volume>28</volume><fpage>614</fpage><lpage>621</lpage><pub-id pub-id-type="pmid">1979723</pub-id></citation></ref><ref id="pgen-0030135-b007"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>BG</given-names></name><name><surname>Koroshetz</surname><given-names>WJ</given-names></name><name><surname>Beal</surname><given-names>MF</given-names></name><name><surname>Rosen</surname><given-names>BR</given-names></name></person-group><year>1993</year><article-title>Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy</article-title><source>Neurology</source><volume>43</volume><fpage>2689</fpage><lpage>2695</lpage><pub-id pub-id-type="pmid">8255479</pub-id></citation></ref><ref id="pgen-0030135-b008"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>BG</given-names></name><name><surname>Rosas</surname><given-names>HD</given-names></name><name><surname>Chen</surname><given-names>YC</given-names></name><name><surname>Makabe</surname><given-names>T</given-names></name><name><surname>Myers</surname><given-names>R</given-names></name><etal/></person-group><year>1998</year><article-title>1H NMR spectroscopy studies of Huntington's disease: Correlations with CAG repeat numbers</article-title><source>Neurology</source><volume>50</volume><fpage>1357</fpage><lpage>1365</lpage><pub-id pub-id-type="pmid">9595987</pub-id></citation></ref><ref id="pgen-0030135-b009"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koroshetz</surname><given-names>WJ</given-names></name><name><surname>Jenkins</surname><given-names>BG</given-names></name><name><surname>Rosen</surname><given-names>BR</given-names></name><name><surname>Beal</surname><given-names>MF</given-names></name></person-group><year>1997</year><article-title>Energy metabolism defects in Huntington's disease and effects of coenzyme Q10</article-title><source>Ann Neurol</source><volume>41</volume><fpage>160</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">9029064</pub-id></citation></ref><ref id="pgen-0030135-b010"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lodi</surname><given-names>R</given-names></name><name><surname>Schapira</surname><given-names>AH</given-names></name><name><surname>Manners</surname><given-names>D</given-names></name><name><surname>Styles</surname><given-names>P</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name><etal/></person-group><year>2000</year><article-title>Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy</article-title><source>Ann Neurol</source><volume>48</volume><fpage>72</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">10894218</pub-id></citation></ref><ref id="pgen-0030135-b011"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saft</surname><given-names>C</given-names></name><name><surname>Zange</surname><given-names>J</given-names></name><name><surname>Andrich</surname><given-names>J</given-names></name><name><surname>Muller</surname><given-names>K</given-names></name><name><surname>Lindenberg</surname><given-names>K</given-names></name><etal/></person-group><year>2005</year><article-title>Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease</article-title><source>Mov Disord</source><volume>20</volume><fpage>674</fpage><lpage>679</lpage><pub-id pub-id-type="pmid">15704211</pub-id></citation></ref><ref id="pgen-0030135-b012"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seong</surname><given-names>IS</given-names></name><name><surname>Ivanova</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Choo</surname><given-names>YS</given-names></name><name><surname>Fossale</surname><given-names>E</given-names></name><etal/></person-group><year>2005</year><article-title>HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism</article-title><source>Hum Mol Genet</source><volume>14</volume><fpage>2871</fpage><lpage>2880</lpage><pub-id pub-id-type="pmid">16115812</pub-id></citation></ref><ref id="pgen-0030135-b013"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clabough</surname><given-names>EB</given-names></name><name><surname>Zeitlin</surname><given-names>SO</given-names></name></person-group><year>2006</year><article-title>Deletion of the triplet repeat encoding polyglutamine within the mouse Huntington's disease gene results in subtle behavioral/motor phenotypes in vivo and elevated levels of ATP with cellular senescence in vitro</article-title><source>Hum Mol Genet</source><volume>15</volume><fpage>607</fpage><lpage>623</lpage><pub-id pub-id-type="pmid">16403806</pub-id></citation></ref><ref id="pgen-0030135-b014"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McGill</surname><given-names>JK</given-names></name><name><surname>Beal</surname><given-names>MF</given-names></name></person-group><year>2006</year><article-title>PGC-1alpha, a new therapeutic target in Huntington's disease?</article-title><source>Cell</source><volume>127</volume><fpage>465</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">17081970</pub-id></citation></ref><ref id="pgen-0030135-b015"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Choo</surname><given-names>YS</given-names></name><name><surname>Johnson</surname><given-names>GV</given-names></name><name><surname>MacDonald</surname><given-names>M</given-names></name><name><surname>Detloff</surname><given-names>PJ</given-names></name><name><surname>Lesort</surname><given-names>M</given-names></name></person-group><year>2004</year><article-title>Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release</article-title><source>Hum Mol Genet</source><volume>13</volume><fpage>1407</fpage><lpage>1420</lpage><pub-id pub-id-type="pmid">15163634</pub-id></citation></ref><ref id="pgen-0030135-b016"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Panov</surname><given-names>AV</given-names></name><name><surname>Gutekunst</surname><given-names>CA</given-names></name><name><surname>Leavitt</surname><given-names>BR</given-names></name><name><surname>Hayden</surname><given-names>MR</given-names></name><name><surname>Burke</surname><given-names>JR</given-names></name><etal/></person-group><year>2002</year><article-title>Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines</article-title><source>Nat Neurosci</source><volume>5</volume><fpage>731</fpage><lpage>736</lpage><pub-id pub-id-type="pmid">12089530</pub-id></citation></ref><ref id="pgen-0030135-b017"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Panov</surname><given-names>AV</given-names></name><name><surname>Burke</surname><given-names>JR</given-names></name><name><surname>Strittmatter</surname><given-names>WJ</given-names></name><name><surname>Greenamyre</surname><given-names>JT</given-names></name></person-group><year>2003</year><article-title>In vitro effects of polyglutamine tracts on Ca2&#x0002b;-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease</article-title><source>Arch Biochem Biophys</source><volume>410</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12559971</pub-id></citation></ref><ref id="pgen-0030135-b018"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trettel</surname><given-names>F</given-names></name><name><surname>Rigamonti</surname><given-names>D</given-names></name><name><surname>Hilditch-Maguire</surname><given-names>P</given-names></name><name><surname>Wheeler</surname><given-names>VC</given-names></name><name><surname>Sharp</surname><given-names>AH</given-names></name><etal/></person-group><year>2000</year><article-title>Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells</article-title><source>Hum Mol Genet</source><volume>9</volume><fpage>2799</fpage><lpage>2809</lpage><pub-id pub-id-type="pmid">11092756</pub-id></citation></ref><ref id="pgen-0030135-b019"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>L</given-names></name><name><surname>Jeong</surname><given-names>H</given-names></name><name><surname>Borovecki</surname><given-names>F</given-names></name><name><surname>Parkhurst</surname><given-names>CN</given-names></name><name><surname>Tanese</surname><given-names>N</given-names></name><etal/></person-group><year>2006</year><article-title>Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration</article-title><source>Cell</source><volume>127</volume><fpage>59</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">17018277</pub-id></citation></ref><ref id="pgen-0030135-b020"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weydt</surname><given-names>P</given-names></name><name><surname>Pineda</surname><given-names>VV</given-names></name><name><surname>Torrence</surname><given-names>AE</given-names></name><name><surname>Libby</surname><given-names>RT</given-names></name><name><surname>Satterfield</surname><given-names>TF</given-names></name><etal/></person-group><year>2006</year><article-title>Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration</article-title><source>Cell Metab</source><volume>4</volume><fpage>349</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">17055784</pub-id></citation></ref><ref id="pgen-0030135-b021"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Milakovic</surname><given-names>T</given-names></name><name><surname>Johnson</surname><given-names>GV</given-names></name></person-group><year>2005</year><article-title>Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin</article-title><source>J Biol Chem</source><volume>280</volume><fpage>30773</fpage><lpage>30782</lpage><pub-id pub-id-type="pmid">15983033</pub-id></citation></ref><ref id="pgen-0030135-b022"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gines</surname><given-names>S</given-names></name><name><surname>Seong</surname><given-names>IS</given-names></name><name><surname>Fossale</surname><given-names>E</given-names></name><name><surname>Ivanova</surname><given-names>E</given-names></name><name><surname>Trettel</surname><given-names>F</given-names></name><etal/></person-group><year>2003</year><article-title>Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice</article-title><source>Hum Mol Genet</source><volume>12</volume><fpage>497</fpage><lpage>508</lpage><pub-id pub-id-type="pmid">12588797</pub-id></citation></ref><ref id="pgen-0030135-b023"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>Z</given-names></name><name><surname>Choo</surname><given-names>YS</given-names></name><name><surname>Lesort</surname><given-names>M</given-names></name></person-group><year>2006</year><article-title>Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington's disease knock-in striatal cells</article-title><source>Eur J Neurosci</source><volume>23</volume><fpage>1701</fpage><lpage>1710</lpage><pub-id pub-id-type="pmid">16623826</pub-id></citation></ref><ref id="pgen-0030135-b024"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nasr</surname><given-names>P</given-names></name><name><surname>Gursahani</surname><given-names>HI</given-names></name><name><surname>Pang</surname><given-names>Z</given-names></name><name><surname>Bondada</surname><given-names>V</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><etal/></person-group><year>2003</year><article-title>Influence of cytosolic and mitochondrial Ca2&#x0002b;, ATP, mitochondrial membrane potential, and calpain activity on the mechanism of neuron death induced by 3-nitropropionic acid</article-title><source>Neurochem Int</source><volume>43</volume><fpage>89</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">12620277</pub-id></citation></ref><ref id="pgen-0030135-b025"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Greenberg</surname><given-names>SA</given-names></name><name><surname>Kong</surname><given-names>SW</given-names></name><name><surname>Altschuler</surname><given-names>J</given-names></name><name><surname>Kohane</surname><given-names>IS</given-names></name><etal/></person-group><year>2005</year><article-title>Discovering statistically significant pathways in expression profiling studies</article-title><source>Proc Natl Acad Sci U S A</source><volume>102</volume><fpage>13544</fpage><lpage>13549</lpage><pub-id pub-id-type="pmid">16174746</pub-id></citation></ref><ref id="pgen-0030135-b026"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sipione</surname><given-names>S</given-names></name><name><surname>Rigamonti</surname><given-names>D</given-names></name><name><surname>Valenza</surname><given-names>M</given-names></name><name><surname>Zuccato</surname><given-names>C</given-names></name><name><surname>Conti</surname><given-names>L</given-names></name><etal/></person-group><year>2002</year><article-title>Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses</article-title><source>Hum Mol Genet</source><volume>11</volume><fpage>1953</fpage><lpage>1965</lpage><pub-id pub-id-type="pmid">12165557</pub-id></citation></ref><ref id="pgen-0030135-b027"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Almeida</surname><given-names>A</given-names></name><name><surname>Moncada</surname><given-names>S</given-names></name><name><surname>Bolanos</surname><given-names>JP</given-names></name></person-group><year>2004</year><article-title>Nitric oxide switches on glycolysis through the AMP protein kinase and 6-phosphofructo-2-kinase pathway</article-title><source>Nat Cell Biol</source><volume>6</volume><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">14688792</pub-id></citation></ref><ref id="pgen-0030135-b028"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calvo</surname><given-names>S</given-names></name><name><surname>Jain</surname><given-names>M</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Sheth</surname><given-names>SA</given-names></name><name><surname>Chang</surname><given-names>B</given-names></name><etal/></person-group><year>2006</year><article-title>Systematic identification of human mitochondrial disease genes through integrative genomics</article-title><source>Nat Genet</source><volume>38</volume><fpage>576</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">16582907</pub-id></citation></ref><ref id="pgen-0030135-b029"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hodges</surname><given-names>A</given-names></name><name><surname>Strand</surname><given-names>AD</given-names></name><name><surname>Aragaki</surname><given-names>AK</given-names></name><name><surname>Kuhn</surname><given-names>A</given-names></name><name><surname>Sengstag</surname><given-names>T</given-names></name><etal/></person-group><year>2006</year><article-title>Regional and cellular gene expression changes in human Huntington's disease brain</article-title><source>Hum Mol Genet</source><volume>15</volume><fpage>965</fpage><lpage>977</lpage><pub-id pub-id-type="pmid">16467349</pub-id></citation></ref><ref id="pgen-0030135-b030"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>JK</given-names></name><name><surname>Auerbach</surname><given-names>W</given-names></name><name><surname>Duyao</surname><given-names>MP</given-names></name><name><surname>Vonsattel</surname><given-names>JP</given-names></name><name><surname>Gusella</surname><given-names>JF</given-names></name><etal/></person-group><year>1997</year><article-title>Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion</article-title><source>Nat Genet</source><volume>17</volume><fpage>404</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">9398841</pub-id></citation></ref><ref id="pgen-0030135-b031"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reiner</surname><given-names>A</given-names></name><name><surname>Dragatsis</surname><given-names>I</given-names></name><name><surname>Zeitlin</surname><given-names>S</given-names></name><name><surname>Goldowitz</surname><given-names>D</given-names></name></person-group><year>2003</year><article-title>Wild-type huntingtin plays a role in brain development and neuronal survival</article-title><source>Mol Neurobiol</source><volume>28</volume><fpage>259</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">14709789</pub-id></citation></ref><ref id="pgen-0030135-b032"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Raamsdonk</surname><given-names>JM</given-names></name><name><surname>Gibson</surname><given-names>WT</given-names></name><name><surname>Pearson</surname><given-names>J</given-names></name><name><surname>Murphy</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>G</given-names></name><etal/></person-group><year>2006</year><article-title>Body weight is modulated by levels of full-length huntingtin</article-title><source>Hum Mol Genet</source><volume>15</volume><fpage>1513</fpage><lpage>1523</lpage><pub-id pub-id-type="pmid">16571604</pub-id></citation></ref><ref id="pgen-0030135-b033"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Woda</surname><given-names>JM</given-names></name><name><surname>Calzonetti</surname><given-names>T</given-names></name><name><surname>Hilditch-Maguire</surname><given-names>P</given-names></name><name><surname>Duyao</surname><given-names>MP</given-names></name><name><surname>Conlon</surname><given-names>RA</given-names></name><etal/></person-group><year>2005</year><article-title>Inactivation of the Huntington's disease gene (Hdh) impairs anterior streak formation and early patterning of the mouse embryo</article-title><source>BMC Dev Biol</source><volume>5</volume><fpage>17</fpage><pub-id pub-id-type="pmid">16109169</pub-id></citation></ref><ref id="pgen-0030135-b034"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dragatsis</surname><given-names>I</given-names></name><name><surname>Efstratiadis</surname><given-names>A</given-names></name><name><surname>Zeitlin</surname><given-names>S</given-names></name></person-group><year>1998</year><article-title>Mouse mutant embryos lacking huntingtin are rescued from lethality by wild-type extraembryonic tissues</article-title><source>Development</source><volume>125</volume><fpage>1529</fpage><lpage>1539</lpage><pub-id pub-id-type="pmid">9502734</pub-id></citation></ref><ref id="pgen-0030135-b035"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hilditch-Maguire</surname><given-names>P</given-names></name><name><surname>Trettel</surname><given-names>F</given-names></name><name><surname>Passani</surname><given-names>LA</given-names></name><name><surname>Auerbach</surname><given-names>A</given-names></name><name><surname>Persichetti</surname><given-names>F</given-names></name><etal/></person-group><year>2000</year><article-title>Huntingtin: An iron-regulated protein essential for normal nuclear and perinuclear organelles</article-title><source>Hum Mol Genet</source><volume>9</volume><fpage>2789</fpage><lpage>2797</lpage><pub-id pub-id-type="pmid">11092755</pub-id></citation></ref><ref id="pgen-0030135-b036"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>MacDonald</surname><given-names>ME</given-names></name></person-group><year>2003</year><article-title>Huntingtin: Alive and well and working in middle management</article-title><source>Sci STKE</source><volume>2003</volume><fpage>pe48</fpage><pub-id pub-id-type="pmid">14600292</pub-id></citation></ref><ref id="pgen-0030135-b037"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zuccato</surname><given-names>C</given-names></name><name><surname>Tartari</surname><given-names>M</given-names></name><name><surname>Crotti</surname><given-names>A</given-names></name><name><surname>Goffredo</surname><given-names>D</given-names></name><name><surname>Valenza</surname><given-names>M</given-names></name><etal/></person-group><year>2003</year><article-title>Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes</article-title><source>Nat Genet</source><volume>35</volume><fpage>76</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">12881722</pub-id></citation></ref><ref id="pgen-0030135-b038"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Desaint</surname><given-names>S</given-names></name><name><surname>Hansmannel</surname><given-names>F</given-names></name><name><surname>Clemencet</surname><given-names>MC</given-names></name><name><surname>Le Jossic-Corcos</surname><given-names>C</given-names></name><name><surname>Nicolas-Frances</surname><given-names>V</given-names></name><etal/></person-group><year>2004</year><article-title>NFY interacts with the promoter region of two genes involved in the rat peroxisomal fatty acid beta-oxidation: the multifunctional protein type 1 and the 3-ketoacyl-CoA B thiolase</article-title><source>Lipids Health Dis</source><volume>3</volume><fpage>4</fpage><pub-id pub-id-type="pmid">15046640</pub-id></citation></ref><ref id="pgen-0030135-b039"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Droge</surname><given-names>W</given-names></name></person-group><year>2006</year><article-title>Redox regulation in anabolic and catabolic processes</article-title><source>Curr Opin Clin Nutr Metab Care</source><volume>9</volume><fpage>190</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">16607115</pub-id></citation></ref><ref id="pgen-0030135-b040"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hernandez-Montes</surname><given-names>E</given-names></name><name><surname>Pollard</surname><given-names>SE</given-names></name><name><surname>Vauzour</surname><given-names>D</given-names></name><name><surname>Jofre-Montseny</surname><given-names>L</given-names></name><name><surname>Rota</surname><given-names>C</given-names></name><etal/></person-group><year>2006</year><article-title>Activation of glutathione peroxidase via Nrf1 mediates genistein's protection against oxidative endothelial cell injury</article-title><source>Biochem Biophys Res Commun</source><volume>346</volume><fpage>851</fpage><lpage>859</lpage><pub-id pub-id-type="pmid">16780800</pub-id></citation></ref><ref id="pgen-0030135-b041"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>SH</given-names></name><name><surname>Cheng</surname><given-names>AL</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Lam</surname><given-names>S</given-names></name><name><surname>Rao</surname><given-names>M</given-names></name><etal/></person-group><year>2002</year><article-title>Interaction of Huntington disease protein with transcriptional activator Sp1</article-title><source>Mol Cell Biol</source><volume>22</volume><fpage>1277</fpage><lpage>1287</lpage><pub-id pub-id-type="pmid">11839795</pub-id></citation></ref><ref id="pgen-0030135-b042"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname><given-names>W</given-names></name><name><surname>Jeong</surname><given-names>H</given-names></name><name><surname>Cui</surname><given-names>L</given-names></name><name><surname>Krainc</surname><given-names>D</given-names></name><name><surname>Tjian</surname><given-names>R</given-names></name></person-group><year>2005</year><article-title>In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets</article-title><source>Cell</source><volume>123</volume><fpage>1241</fpage><lpage>1253</lpage><pub-id pub-id-type="pmid">16377565</pub-id></citation></ref><ref id="pgen-0030135-b043"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen-Plotkin</surname><given-names>AS</given-names></name><name><surname>Sadri-Vakili</surname><given-names>G</given-names></name><name><surname>Yohrling</surname><given-names>GJ</given-names></name><name><surname>Braveman</surname><given-names>MW</given-names></name><name><surname>Benn</surname><given-names>CL</given-names></name><etal/></person-group><year>2006</year><article-title>Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease</article-title><source>Neurobiol Dis</source><volume>22</volume><fpage>233</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">16442295</pub-id></citation></ref><ref id="pgen-0030135-b044"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takano</surname><given-names>H</given-names></name><name><surname>Gusella</surname><given-names>JF</given-names></name></person-group><year>2002</year><article-title>The predominantly HEAT-like motif structure of huntingtin and its association and coincident nuclear entry with dorsal, an NF-kB/Rel/dorsal family transcription factor</article-title><source>BMC Neurosci</source><volume>3</volume><fpage>15</fpage><pub-id pub-id-type="pmid">12379151</pub-id></citation></ref><ref id="pgen-0030135-b045"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>JR</given-names></name><name><surname>Wakasugi</surname><given-names>N</given-names></name><name><surname>Virelizier</surname><given-names>JL</given-names></name><name><surname>Yodoi</surname><given-names>J</given-names></name><name><surname>Hay</surname><given-names>RT</given-names></name></person-group><year>1992</year><article-title>Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62</article-title><source>Nucleic Acids Res</source><volume>20</volume><fpage>3821</fpage><lpage>3830</lpage><pub-id pub-id-type="pmid">1508666</pub-id></citation></ref><ref id="pgen-0030135-b046"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baughman</surname><given-names>JM</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name></person-group><year>2006</year><article-title>Buffering mitochondrial DNA variation</article-title><source>Nat Genet</source><volume>38</volume><fpage>1232</fpage><lpage>1233</lpage><pub-id pub-id-type="pmid">17072298</pub-id></citation></ref><ref id="pgen-0030135-b047"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>S</given-names></name><name><surname>Gregory</surname><given-names>C</given-names></name><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Shrager</surname><given-names>J</given-names></name><name><surname>Kaiser</surname><given-names>L</given-names></name><etal/></person-group><year>2002</year><article-title>Bioenergetic adaptation of individual human diaphragmatic myofibers to severe COPD</article-title><source>J Appl Physiol</source><volume>92</volume><fpage>1205</fpage><lpage>1213</lpage><pub-id pub-id-type="pmid">11842060</pub-id></citation></ref><ref id="pgen-0030135-b048"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><year>2001</year><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method</article-title><source>Methods</source><volume>25</volume><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">11846609</pub-id></citation></ref><ref id="pgen-0030135-b049"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bolstad</surname><given-names>BM</given-names></name><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Astrand</surname><given-names>M</given-names></name><name><surname>Speed</surname><given-names>TP</given-names></name></person-group><year>2003</year><article-title>A comparison of normalization methods for high density oligonucleotide array data based on variance and bias</article-title><source>Bioinformatics</source><volume>19</volume><fpage>185</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">12538238</pub-id></citation></ref><ref id="pgen-0030135-b050"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Storey</surname><given-names>JD</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name></person-group><year>2003</year><article-title>Statistical significance for genomewide studies</article-title><source>Proc Natl Acad Sci U S A</source><volume>100</volume><fpage>9440</fpage><lpage>9445</lpage><pub-id pub-id-type="pmid">12883005</pub-id></citation></ref><ref id="pgen-0030135-b051"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dennis</surname><given-names>G</given-names><suffix>Jr.</suffix></name><name><surname>Sherman</surname><given-names>BT</given-names></name><name><surname>Hosack</surname><given-names>DA</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><etal/></person-group><year>2003</year><article-title>DAVID: Database for annotation, visualization, and integrated discovery</article-title><source>Genome Biol</source><volume>4</volume><fpage>P3</fpage><pub-id pub-id-type="pmid">12734009</pub-id></citation></ref><ref id="pgen-0030135-b052"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eisen</surname><given-names>MB</given-names></name><name><surname>Spellman</surname><given-names>PT</given-names></name><name><surname>Brown</surname><given-names>PO</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name></person-group><year>1998</year><article-title>Cluster analysis and display of genome-wide expression patterns</article-title><source>Proc Natl Acad Sci U S A</source><volume>95</volume><fpage>14863</fpage><lpage>14868</lpage><pub-id pub-id-type="pmid">9843981</pub-id></citation></ref><ref id="pgen-0030135-b053"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Wong</surname><given-names>WH</given-names></name></person-group><year>2001</year><article-title>Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection</article-title><source>Proc Natl Acad Sci U S A</source><volume>98</volume><fpage>31</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">11134512</pub-id></citation></ref><ref id="pgen-0030135-b054"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gentleman</surname><given-names>RC</given-names></name><name><surname>Carey</surname><given-names>VJ</given-names></name><name><surname>Bates</surname><given-names>DM</given-names></name><name><surname>Bolstad</surname><given-names>B</given-names></name><name><surname>Dettling</surname><given-names>M</given-names></name><etal/></person-group><year>2004</year><article-title>Bioconductor: open software development for computational biology and bioinformatics</article-title><source>Genome Biol</source><volume>5</volume><fpage>R80</fpage><pub-id pub-id-type="pmid">15461798</pub-id></citation></ref><ref id="pgen-0030135-b055"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marinescu</surname><given-names>VD</given-names></name><name><surname>Kohane</surname><given-names>IS</given-names></name><name><surname>Riva</surname><given-names>A</given-names></name></person-group><year>2005</year><article-title>The MAPPER database: A multi-genome catalog of putative transcription factor binding sites</article-title><source>Nucleic Acids Res</source><volume>33</volume><fpage>D91</fpage><lpage>D97</lpage><pub-id pub-id-type="pmid">15608292</pub-id></citation></ref><ref id="pgen-0030135-b056"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><etal/></person-group><year>2005</year><article-title>Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>Proc Natl Acad Sci U S A</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="pmid">16199517</pub-id></citation></ref></ref-list><fn-group><fn id="n104" fn-type="present-address"><p>&#x000a4; Current address: Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America</p></fn><fn id="n102" fn-type="previously-at"><p>A previous version of this article appeared as an Early Online Release on June 27, 2007 (doi:<ext-link ext-link-type="doi" xlink:href="10.1371/journal.pgen.0030135.eor">10.1371/journal.pgen.0030135.eor</ext-link>).</p></fn><fn id="ack1" fn-type="con"><p><bold>Author contributions.</bold> JML, EVI, JFG, and MEM conceived and designed the experiments. JML, EVI, and ISS performed the experiments. JML, EVI, ISS, TC, IK, and MEM analyzed the data. JML and MEM wrote the paper, incorporating comments from EVI, ISS, TC, IK, and JFG. IK, JFG, and MEM obtained the funding to support the work.</p></fn><fn id="ack2" fn-type="financial-disclosure"><p><bold>Funding.</bold> This work was supported by National Institutes of Health Center for Biomedical Computing grant LM008748 (IK); National Institute of Neurological Disorders and Stroke grants NS16367 (JFG and MEM, HD Center Without Walls), and NS32765 (MEM); an anonymous donor; and the Huntington's Disease Society of America (Coalition for the Cure).</p></fn><fn id="ack3" fn-type="conflict"><p><bold>Competing interests.</bold> The authors have declared that no competing interests exist.</p></fn></fn-group></back></article> 